Portal de Periódicos da CAPES

Effects of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women With Primary Hyperparathyroidism

2000; American Medical Association; Volume: 160; Issue: 14 Linguagem: Inglês

10.1001/archinte.160.14.2161

1538-3679

Brandon Orr‐Walker, Margaret C. Evans, Judith Clearwater, Anne Horne, Andrew Grey, Ian R. Reid,

Nutrition and Health in Aging

Background: Long-term treatment of patients with asymptomatic primary hyperparathyroidism remains controversial, but the presence of osteoporosis is regarded as an indication for parathyroidectomy.Hormone replacement therapy (HRT) is a possible alternative therapy in osteopenic postmenopausal women with the disorder, and results of short-term studies suggest a beneficial effect on bone mass comparable to that achieved by parathyroidectomy.Longer-term data are required to further assess the efficacy of this treatment in chronic stable primary hyperparathyroidism. Methods:We report the results of the extension from 2 to 4 years of a randomized, placebo-controlled trial of HRT in postmenopausal women with primary hyperparathyroidism.Of 23 postmenopausal women with primary hyperparathyroidism, 11 received active HRT with conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 5 mg/d, and 12 received placebo.Bone mineral density was measured throughout the skeleton at 6-month intervals using dual-energy x-ray absorptiometry in these women and in 50 normocalcemic age-matched control subjects.None of the 23 patients withdrew during the extension period.